Table 1.
Metastatic sites, frequency and prognosis and peritoneal carcinomatosis.
| Metastatic Site | Frequency | Prognosis (Median Survival) | Ref. | |
|---|---|---|---|---|
| CNS | 0.3–12% | 8.2 months | [9,10,11,12,13] | |
| Eye | 9 cases reported until 2009 | 6.5–16 months | [14,15,16,17,18,19,20,21] | |
| Skin | 1.2% | 12 months (1–41 months) | [22,23,24,25,26,27] | |
| Bones | <3.74% | 7.5 months | [28,29] | |
| Lymph nodes | Supraclavicular | 4% | NR | [30,31,32,33,34,35,36,37,38,39] |
| Inguinal | 0.8–3% | NR | ||
| Mediastinal-Cardiophrenic | 2.3% | 68.9–72.3 months | ||
| Breast | 0.03–0.6% | 16 months (13 days–3.5 months) | [40,41,42,43] | |
| Rare intra-abdominal | Spleen | 2%–3% in epithelial ovarian cancer | NR | [44,45,46,47] |
| Gastrointestinal | Depends on type and stage of diagnosis | <15 months | ||
| Bronchus and Trachea | 10 reports until 2018 | 6–24 months | [5,48,49] | |
| Heart | 2.4–4% | 3–72 months | [22,32,50,51] | |
| Placenta and Fetus | 3 cases reported until now to placenta 0 to fetus | NR | [52,53,54] | |
CNS: Central Nervous System, NR: Not Reported.